Company Overview
Snapshot
Founded in April 1995, Nicast operates with 1–10 employees and has raised a total of $8.28 million across 4 funding rounds from 3 investors. In October 2008, the company received CE Mark approval for its vascular access graft, AVflo.
Business overview
Nicast develops implantable medical devices utilizing electrospun polymer nanofabrics, designed to mimic the body's extracellular matrix for enhanced tissue integration. The company applies nanotechnology and biomaterials to various medical applications, with its flagship product, AVflo, a CE-certified polyurethane vascular access graft, targeting hemodialysis patients to improve care and reduce hospitalization. Nicast collaborates with medical device companies, research institutes, health authorities, and universities across Europe, Asia, and the U.S., operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.
Strategic signal
In October 2008, Nicast secured CE Mark approval for its AVflo vascular access graft, a critical regulatory milestone that validated the device's compliance with European health, safety, and environmental protection standards. This approval was a significant step for the company, enabling market access in Europe and signaling to investors the commercial readiness and potential of its nanofabric medical device technology.
Log in to access full profile ›Company Intelligence Q&A
- What is Nicast's primary product?
- Nicast's primary product is AVflo, a CE-certified polyurethane vascular access graft designed for hemodialysis patients.
- When was Nicast founded?
- Nicast was founded in April 1995.
- What significant regulatory milestone did Nicast achieve?
- In October 2008, Nicast received CE Mark approval for its AVflo vascular access graft.
- Which investors participated in Nicast's funding round in October 2008?
- In October 2008, Nicast received funding from Azritech Ventures and Infinity Group.